OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer
RATIONALE: Studying protein expression in sentinel lymph node tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. It may also help the study of cancer in the future. PURPOSE: This laboratory study is evaluating OX-40 protein expression in the sentinel lymph nodes of patients with cancer.
Checked against the public recordLast updated Feb 10, 2016 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- OHSU Knight Cancer Institute
- Interventions being studied
- Genetic: protein expression analysis; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Procedure: biopsy
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed cancer, including, but not limited to, the following: * Melanoma * Breast cancer * Invasive squamous cell cancer * Other cancers for which patients underwent or will undergo the following: * Adequate archived paraffin-embedded tissue for making slides for immunostaining * Adequate freshly removed sentinel lymph node (and primary tumor, if available) tissue for laboratory assays * Clinical data and date of last follow-up on tumor stage and status must be available * Hormone receptor status not specified PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * Not specified
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- OHSU Knight Cancer InstitutePortland, Oregon
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Feb 10, 2016. Always confirm current availability with the study team.